Gatley S J, Volkow N D, Gifford A N, Fowler J S, Dewey S L, Ding Y S, Logan J
Medical Department, Brookhaven National Laboratory, Upton, NY 11973, USA.
Psychopharmacology (Berl). 1999 Sep 1;146(1):93-100. doi: 10.1007/s002130051093.
Recent studies using positron emission tomography (PET) have established the relationship between an intravenous dose of cocaine and the percentage occupancy of the dopamine transporter in humans, and have documented the requirement of more than 50% occupancy for perception of the "high". The present experiments were conducted to examine dose-occupancy and dose-effect relationships in mice for cocaine and also for methylphenidate, a dopamine uptake blocker used in pediatric psychiatry.
Percentage occupancies of the dopamine transporter by cocaine and methylphenidate were estimated after intravenous injection in mice from the displacement of in vivo binding of [(3)H]cocaine from the striatum. Locomotor activity was measured in a photocell apparatus.
The relationship between drug doses (milligrams of hydrochloride salt per kilogram body weight) and percentage occupancy of the dopamine transporter was indistinguishable for cocaine and methylphenidate, and corresponded to about 50% occupancy at 0.25 mg/kg and about 80% at 1 mg/kg. This was similar to the relationship between drug dose and transporter occupancy, previously measured in human and baboons using [(11)C]cocaine or [(11)C]d-threo-methylphenidate and PET. Methylphenidate increased locomotor activity in the mice substantially more than cocaine at the same dose and the same degree of dopamine-transporter receptor occupancy.
The range of dopamine-transporter occupancy required for behavioral activation in the mice was thus similar to that previously reported for experience of a cocaine- or methylphenidate-induced "high" in human subjects. Our results are consistent with other studies in which both cocaine and methylphenidate were evaluated in animal behavioral assays and were found to have very similar psychopharmacological properties.
近期使用正电子发射断层扫描(PET)的研究已确立静脉注射可卡因剂量与人类多巴胺转运体占有率之间的关系,并记录了产生“快感”感知所需的占有率超过50%。进行本实验以研究可卡因以及儿科精神病学中使用的多巴胺摄取阻滞剂哌醋甲酯在小鼠中的剂量-占有率和剂量-效应关系。
通过静脉注射后,根据纹状体中[³H]可卡因的体内结合置换情况,估算小鼠体内可卡因和哌醋甲酯对多巴胺转运体的占有率。在光电装置中测量运动活性。
可卡因和哌醋甲酯的药物剂量(每千克体重的盐酸盐毫克数)与多巴胺转运体占有率之间的关系无法区分,在0.25mg/kg时约为50%占有率,在1mg/kg时约为80%占有率。这与先前在人类和狒狒中使用[¹¹C]可卡因或[¹¹C]d-苏式-哌醋甲酯及PET测量的药物剂量与转运体占有率之间的关系相似。在相同剂量和相同多巴胺转运体受体占有率程度下,哌醋甲酯比可卡因更显著地增加小鼠的运动活性。
因此,小鼠行为激活所需的多巴胺转运体占有率范围与先前报道的人类受试者中可卡因或哌醋甲酯诱导的“快感”体验所需的范围相似。我们的结果与其他研究一致,在这些研究中,可卡因和哌醋甲酯均在动物行为试验中进行评估,并且发现具有非常相似的精神药理学特性。